Company news

Acumen Pharmaceuticals, Inc. news in 2023

Acumen Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

November 12, 2023

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

November 12, 2023

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

November 5, 2023

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

August 7, 2023

Acumen Announces Pricing of Upsized $130 Million Public Offering

July 17, 2023

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

July 16, 2023

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

July 15, 2023

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

May 8, 2023

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

May 1, 2023

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

March 26, 2023

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

March 19, 2023

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

February 12, 2023

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

January 3, 2023

Calls in 2023

Decks in 2023